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Abstract
Background: The large clinical trials proved that Basal-Bolus (BB) insulin therapy was effective in the prevention
of diabetic complications and their progression. However, BB therapy needs multiple insulin injections per a day.
In this regard, a biphasic insulin analogue needs only twice-daily injections, and is able to correct postprandial
hyperglycemia. Therefore it may achieve the blood glucose control as same as that of BB therapy and prevent the
diabetic complications including macroangiopathy.
Methods: In PROBE (Prospective, Randomized, Open, Blinded-Endpoint) design, forty-two type 2 diabetic
patients (male: 73.8%, median(inter quartile range) age: 64.5(56.8~71.0)years) with secondary failure of
sulfonylurea (SU) were randomly assigned to BB therapy with a thrice-daily insulin aspart and once-daily basal
insulin (BB group) or to conventional therapy with a twice-daily biphasic insulin analogue (30 Mix group), and were
followed up for 6 months to compare changes in HbA1c, daily glycemic profile, intima-media thickness (IMT) of
carotid artery, adiponectin levels, amounts of insulin used, and QOL between the two groups.
Results: After 6 months, HbA1c was significantly reduced in both groups compared to baseline (30 Mix;
9.3(8.1~11.3) → 7.4(6.9~8.7)%, p < 0.01, vs BB;8.9(7.7~10.0) → 6.9(6.2~7.3)%, p < 0.01), with no significant
difference between the groups in percentage change in HbA1c (30 Mix; -14.7(-32.5~-7.5)% vs BB -17.8(-30.1~-
11.1)%, p = 0.32). There was a significant decrease in daily glycemic profile at all points except dinner time in both
groups compared to baseline. There was a significant increase in the amount of insulin used in the 30 Mix group
after treatment compared to baseline (30 Mix;0.30(0.17~0.44) → 0.39(0.31~0.42) IU/kg, p = 0.01). There was no
significant difference in IMT, BMI, QOL or adiponectin levels in either group compared to baseline.
Conclusion: Both BB and 30 mix group produced comparable reductions in HbA1c in type 2 diabetic patients
with secondary failure. There was no significant change in IMT as an indicator of early atherosclerotic changes
between the two groups. The basal-bolus insulin therapy may not be necessarily needed if the type 2 diabetic
patients have become secondary failure.
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Background
The goal of diabetes management consists in the preven-
tion of diabetic complications, as well as their progres-
sion, by achieving favorable control over glycemic and
other risk factors [1]. Insulin regimens currently in use
include conventional once- or twice-daily insulin injec-
tion therapy, and intensive insulin therapy with a rapid-
acting insulin analogue administered three times daily
before meals to reproduce the physiologic insulin secre-
tion dynamics seen in healthy individuals complemented
by Neutral Protamine Hargedorn (NPH) or long-acting
insulin analogue injections administered at night on an
on-demand basis.
Findings from large-scale epidemiological studies, such as
the Diabetes Control Complication Trial (DCCT) [2,3]
and the Kumamoto Study [4], clearly demonstrate that
intensive insulin therapy significantly reduces the inci-
dence of diabetic complications as well as prevents disease
progression in type 1 and type 2 diabetic patients com-
pared to conventional insulin therapy.
However, an international meeting jointly held by the
WHO and Juvenile Diabetes Foundation International in
1985 pointed to a need for insulin formulations that
could be administered immediately before meals, in con-
trast to the rapid-acting insulin formulations that needed
to be administered 30 minutes before meals, with a blood
concentration profile that could mimic the dynamics of
insulin secretion that occur postprandially in healthy
individuals [5]. This led to the insulin aspart and insulin
Lispro being developed and approved for clinical use in
the 1990's.
While intensive insulin therapy using these formulations
offered more physiologic and rigorous glycemic control
than with conventional insulin formulations, the use of
these formulations involved multiple injections, thus
often leading to poor patient acceptance of the treatment
offered, as well as to some injections being missed.
In the late 1990s, it was demonstrated through the
DECODE study [6] and the Funagata study [7] that high
2-hour glucose levels after an oral glucose tolerance test
(OGTT) are associated with increased risk for cardiovascu-
lar disease compared to high fasting glucose levels, which
led to more rigorous correction of postprandial hypergly-
cemia being called for in the management of diabetes.
A biphasic insulin analogue preparation was approved
and became available overseas in 2000 and in Japan in
2003. This biphasic insulin analogue consists of 30% free
and 70% protamine-bound insulin aspart, and is expected
with its twice-daily pre-meal injections to improve patient
compliance to insulin injection therapy as well as the
quality of life (QOL) of patients given the treatment,
while at the same time improving postprandial hypergly-
cemia better than conventional mixed preparations, thus
potentially reducing the risk for cardiovascular disease.
In type 1 diabetes in which endogenous insulin secretion
is completely depleted, basal-bolus insulin therapy with
an ultra rapid-acting insulin analogue represents an opti-
mal therapeutic choice as it closely mimics physiologic
insulin secretion. In contrast, in type 2 diabetic patients
whose endogenous insulin secretion is preserved to a cer-
tain extent, however, twice-daily insulin injection therapy
using a biphasic insulin analogue may be able to produce
comparable glycemic control to that achieved with basal-
bolus therapy using an ultra rapid-acting insulin ana-
logue, thus potentially commending itself as viable a ther-
apeutic option as basal-bolus therapy in preventing
diabetic complications, including macrovascular compli-
cations.
Furthermore, it was also assumed that biphasic insulin
analogues might have a role in facilitating insulin therapy
for type 2 diabetes in the clinical setting, thus contributing
to overall improved QOL with insulin therapy.
The aim of this study was the comparison of efficacy
between a twice-daily insulin regimen using a biphasic
insulin analogue regimen and basal-bolus regimen using
thrice-daily ultra rapid-acting insulin analogue in these
patients in type 2 diabetic patients with secondary failure
of sulfonylureas(SU). Furthermore, intima-media thick-
ness (IMT) [8] was measured in all patients given these
regimens to compare their efficacy in preventing macrov-
ascular complications, with adiponectin levels and
patient QOL also compared between the treatment
groups.
Methods
Subjects and Methods
This study was a single-center study with a prospective,
randomized, open, blinded-endpoint evaluation
(PROBE) design in type 2 diabetic patients being treated
on an outpatient basis at our clinic, who ranged in age
between 20 years of age or older but younger than 80
years old, and who had secondary failure. Secondary fail-
ure was defined as patients who even were receiving max-
imally tolerated doses of sulfonylurea and failed to
achieve HbA1c < 8%. The study subjects were randomly
assigned to twice-daily insulin therapy with BIAsp70/30
(NovoRapid 30 Mix®), a biphasic insulin analogue formu-
lation given twice daily immediately before breakfast and
dinner (30 Mix group), or to basal-bolus insulin therapy
with insulin aspart (NovoRapid®) in combination with
NPH insulin injected at night on an on-demand basis (BB
group). A computer-assisted, least square method wasCardiovascular Diabetology 2008, 7:16 http://www.cardiab.com/content/7/1/16
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used in random assignment to ensure that there was no
baseline difference in gender, age, BMI, HbA1c, or dura-
tion of SU use between the two groups.
Prior to starting the subjects on insulin therapy, all SU was
discontinued in the subjects, while all insulin-sensitizing
agents (metformin or thiazolidinedione derivatives)
being concurrently used with SU in the subjects were con-
tinued. All α-glucosidase inhibitors or phenylalanine
derivatives being concurrently used with SU were discon-
tinued. Use of any new oral hypoglycemic agents (OHA)
in the subjects was not allowed during follow-up.
All subjects agreed to self-measuring their blood glucose
levels (SMBG) at home during follow-up after initiation
of insulin therapy.
At initiation of insulin therapy, all subjects were hospital-
ized and their insulin dose was adjusted at the discretion
of the attending physician every 2 to 3 days for the first
week of treatment in an attempt to achieve fasting glucose
levels less than 130 mg/dl and 2-hour postprandial glu-
cose levels less than 180 mg/dl as per the definition of
"favorable glycemic control" given in the Japanese Guide-
lines for the Management of Diabetes by Japan Diabetes
Society. After hospital discharge, the subjects were asked
to visit the outpatient clinic once a month, when the
attending physician adjusted the insulin dose with the
goal of achieving HbA1c < 6.5% in mind, in light of the
self-measured glucose levels reported by the subjects.
Laboratory procedures
Parameters evaluated at hospital admission included
height, body weight, blood pressure after resting, HbA1c,
daily glycemic profile (in terms of 7-point glucose meas-
urements; immediately before and 120 minutes after
breakfast, lunch, and dinner, at bedtime), total amount of
insulin used, and adiponectin levels, and these parame-
ters were evaluated once again after 24 weeks of treatment
to allow comparison between the treatment groups for
changes in these variables.
Carotid B-Mode Ultrasound
Ultrasonographic scanning of carotid artery was per-
formed at the beginning and the end of the study. A series
of ultrasonographic scans was performed using an echoto-
mographic system (NEMIO SSA-550A, Toshiba Medical
System Corporation, Tokyo) with an electrical linear
transducer (mid frequency of 7.5 MHz).
The carotid IMT defined by Pignoli et al. was measured as
the distance from the leading edge of the first echogenic
line to the leading edge of the second echogenic line[9].
Measurement of IMT was conducted by two well-trained
physician. IMT in internal carotid artery was evaluated in
the subjects through examination of the common carotid
artery, carotid sinus, and internal carotid artery by ultra-
sound, and the sites associated with the greatest IMT
observed on the left and right were measured to obtain
maximum IMT values for comparison, in accordance with
Japanese Guidelines for Ultrasonic Assessment of Carotid
Artery Disease by the Japan Academy of Neurosonology
and other previous reports[10,11].
Quality of life scoring
In addition, the quality of life (QOL) of the subjects was
evaluated by using a Japanese version of the diabetes treat-
ment satisfaction questionnaire (DTSQ) developed by C.
Bradley [12]. This questionnaire is intended to elicit
responses to each of the 8 questions listed in terms of 6-
graded answers, where the higher the scores for questions
1, 4, 5, 6, 7, and 8, the higher the QOL of the respondents,
while, in contrast, the higher the scores for questions 2
and 3, the lower the QOL of the respondents. In this
study, using the maximum total score of 36 for questions
1, 4, 5, 6, 7 and 8 combined, the treatment groups were
compared for changes in the DTSQ scores from baseline.
Statistical Analysis
Data were expressed by medians (inter quartile range).
Statistical analysis was performed on each of the parame-
ters evaluated for each group by using Wilcoxon signed-
rank test to see if there was any significant difference in
each parameter between baseline and after treatment. In
addition, each of the parameters evaluated was examined
for percentage change in the 6-month follow-up and com-
pared between the treatment groups by using Wilcoxon
rank-sum test. The computer program used for statistical
analysis was SPSS ver.15.
The study protocol for the current study was approved by
the Institutional Review Board of the Jikei University
School of Medicine, and was conducted with informed
consent obtained from all participating subjects (Current
Controlled Trials number, NCT00348231).
Results
Of the 53 participants screened, 42 subjects were ran-
domly assigned at the ratio of 1:1 to the 30 Mix group (n
= 21) or the BB group (n = 21). Of the 11 subjects who
dropped out or were lost to follow-up, 2 subjects had
malignancy detected during hospitalization, 5 failed to
adhere to the injection instructions, and 4 stopped pre-
senting to the clinic after hospital discharge (Figure 1).
The clinical characteristics of the subjects are given in
Table 1. The median (inter quartile range) age of the sub-
jects was 64.5(56.8~71.0) years of age; the ratio of males,
73.8%; the median BMI, 23.7(21.9~26.1) kg/m2; the
median HbA1c, 9.2(7.9~10.6)%; and the median dura-Cardiovascular Diabetology 2008, 7:16 http://www.cardiab.com/content/7/1/16
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tion of SU use, 11.0(6.0~15.3) years. There was no signif-
icant difference in the distribution of these values between
the groups.
HbA1c was significantly reduced in both groups after 6
months of insulin therapy compared to baseline (see
Additional file 1; 30 Mix;9.3(8.1~11.3) → 7.4(6.9~8.7)%,
p < 0.01, vs BB;8.9(7.7~10.0) → 6.9(6.2~7.3)%, p <
0.01), with no significant difference noted in percentage
change in HbA1c between the groups (Figure 2; 30 Mix; -
14.7(-32.5~-7.5)% vs BB -17.8(-30.1~-11.1)%, p = 0.32).
There was a significant decrease in daily glycemic profile
at all time points except dinner following initiation of
insulin therapy in both groups compared to baseline (see
Additional file 1), with no significant difference noted in
percentage change in glucose levels between the groups
(Figure 3).
There was no significant difference seen in percent change
in insulin used per kilo of body weight between the
groups (Figure 2; 30 Mix; 18.7(-2.4~-58.7)% vs BB; 5.3(-
19.0~45.3, p = 0.18). However, the 30 Mix group tended
to increase the amount of insulin used comparing with
the BB group. While there was a significant increase in the
absolute amount of insulin used in the 30 Mix group after
6 months of insulin therapy compared to baseline (see
Additional file 1; 30 Mix;0.30(0.17~0.44) → 0.39
(0.31~0.42) IU/kg, p = 0.01), there was no significant dif-
ference in this parameter in the BB group compared to
baseline (see Additional file 1; BB; 0.31(0.24~0.49) →
0.44(0.27~0.53) IU/kg, p = 0.31).
While there was no significant difference in carotid IMT in
either group compared to baseline (see Additional file 1;
30 Mix; 1.5(1.2~2.2) → 1.4(1.1~2.1), p = 0.93 vs
BB;1.8(1.3~2.5)  → 1.8(1.2~2.5)mm, p = 0.50), there
tended to be a decrease in percentage change in IMT in the
BB group (Figure 2; 30 Mix; -6.7(-25.5~17.3)% vs BB; -
4.8(-20.0~11.8)%, p = 0.60).
There was significant difference in adiponectin levels in
30 Mix group between before and after insulin therapy
(see Additional file 1; 30 Mix; 7.5(5.3~9.0) →
7.8(6.9~9.5)  μg/ml, p = 0.02 vs BB;7.0(5.2~14.5) →
9.0(6.2~14.0) μg/ml, p = 0.16). However, there tended to
be an increase in this parameter in both groups, while this
was not statistically significant (Figure 2; 30 Mix;
10.3(2.0~37.8)% vs BB; 24.4(-11.6~52.9)%, p = 0.80).
The patient QOL tended to improve after initiation of
therapy in both groups, (see Additional file 1; 30 Mix;
26.0(21.5~28.5)  → 26.0(21.0~31.5), p = 0.40 vs
BB;22.0(18.0~26.5) → 25.0(18.8~29.3), p = 0.06), how-
ever no significant difference noted, either, in percentage
change in this parameter between the groups (Figure 2; 30
Mix; 3.3(-13.6~26.8)% vs BB; 2.9(-3.8~8.0)%, p = 0.81).
Discussion
The current study in patients with secondary failure dem-
onstrated that no significant difference was seen in
changes in HbA1c or in percentage change in HbA1c after
6 months of therapy between BB and 30 Mix group.
The DCCT [2,3] and the Kumamoto study [4] provided
further lines of evidence showing that, in both type 1 and
type 2 diabetes, intensive insulin therapy is better able to
prevent diabetic complications than conventional insulin
therapy, with the added benefit of favorable HbA1c status
achieved in patients given intensive insulin therapy.
In contrast to these reports, our study with its focus on
HbA1c as the primary indicator of glycemic control
showed that comparable results can be obtained both in
type 2 diabetic patients given basal-bolus insulin therapy
(BB group) and in those given conventional therapy with
a biphasic insulin analogue (30 Mix group).
Trial profile Figure 1
Trial profile.
53 underwent randomization 
࡮ Type 2 diabetes 
࡮ ҈20 and <80 old 
࡮ Secondary failure of sulfonylurea 
࡮ Insulin native 
࡮ Agreed on SMBG   
࡮ Provided informed consent 
Assigned
21 to 30mix 
࡮ Male; 16 
࡮ Female; 5 
21 to Basal Bolus 
࡮ Male; 15 
࡮ Female; 6 
11 discontinued 
࡮ found cancer 
࡮ lost to follow-up 
࡮ withdrew participation Cardiovascular Diabetology 2008, 7:16 http://www.cardiab.com/content/7/1/16
Page 5 of 8
(page number not for citation purposes)
The present study also showed that, while there was no
significant difference between two treatment groups in
percentage change in HbA1c, however the median HbA1c
after 6 months of treatment higher in the 30 Mix group
(30 Mix group 7.4(6.9~8.7)% vs BB group 6.9(6.2~7.3)%,
p = 0.02). Because HbA1c level of the 30 Mix group
tended to be higher than that of the BB group in the study
started point (Table 1; 30 mix 9.3 (8.1–11.3)% vs BB 8.9
(7.7–10.0)%, p = 0.24). The mean absolute glucose level
after each meal in the 30 Mix group was in excess of 200
mg/dl, suggesting that postprandial glucose levels tended
to be higher in the 30 Mix group. Therefore, it is suggested
that improving postprandial hyperglycemia is required to
achieve greater HbA1c control in the 30 Mix group in our
study. In this regard, of note, Monnier et al[13] reported
the relative contribution of fasting plasma glucose (FPG)
versus postprandial plasma glucose (PPG) to changes in
HbA1c as being 30% versus 70% in patients with HbA1c
ranging under 7.3%, respectively, while at the same time
adding that this ratio comes close to 50% versus 50% in
patients with HbA1c ranging between 7.3% and 8.4%.
Woerle et al. [14] also showed that glycemic control to
FPG 100 mg/dL or lower results in HbA1c 7% or lower
being achieved in 64% of patients, while glycemic control
to PPG 140 mg/dL or lower results in HbA1c 7% or lower
being achieved in 94% of patients.
While there was no significant difference noted between
the treatment groups in changes in BMI after initiation of
insulin therapy, BMI tended to increase in the 30 Mix
group, possibly due to the increase in body weight associ-
ated with the amount of insulin use that tended to
increase in the 30 Mix group.
In our study, IMT was measured as a surrogate endpoint
to examine whether or not insulin therapy might promote
atherosclerosis. There was virtually no difference in IMT
values from baseline in both the 30 Mix and BB group.
However, our study had limitation that the observational
period of 6 months might not be long enough to evaluate
atherosclerosis.
In this regard, postprandial glucose levels were evaluated
as factors linked to IMT. Postprandial hyperglycemia has
long been known to be a risk factor for diabetic macrovas-
cular complications [6,7,15-17], and in agreement with
this, our study results also demonstrated that daily glyc-
emic profile tended to be higher after lunch in the 30 Mix
group after 6 months of insulin therapy than in the BB
group (unpublished data), suggesting that more rigorous
glycemic control may have contributed to the trend for a
decrease in IMT becoming manifest in the 30 Mix group.
Also, adiponectin was evaluated as factors linked to IMT.
Adiponectin tended to increase in both groups after initi-
ation of insulin therapy, while there was no significant
difference between the two groups. In this regard, IMT and
adiponectin are reported to be negatively correlated [18],
consistently with the results of the current study.
With regard to the relationship between exogenous insu-
lin and adiponectin in vivo, there is one study in pediatric
type 1 diabetes reporting an increase in adiponectin 1
month after initiation of insulin therapy [19], while, to
date, there is no published study in type 2 diabetes. How-
ever, adiponectin secretion is known to be influenced by
factors that induce insulin resistance, which include
tumor necrosis factor (TNF)-α [20], interleukin (IL)-6
[21], C-reactive protein (CRP) [22], lipid metabolism
[23], diet and exercise habits [24,25]. Further research is
required to clarify how these insulin resistance-related fac-
tors, as they come into play as confounding factors, may
behave after initiation of insulin therapy to elucidate the
relationship between exogenous insulin and adiponectin.
QOL was shown to improve in both groups after initia-
tion of insulin therapy compared to baseline, with no sig-
nificant difference shown between the groups. The study
subjects appear to have felt not so much stress in starting
insulin therapy as satisfaction in being able to achieve bet-
ter glycemic control, which likely contributed to an
increase in their QOL. However, the current study did not
include a crossover design, and the subjects stayed on the
Table 1: Clinical characteristics of study subjects
Total 30 mix Basal Bolus p
n4 2 2 1 2 1
Male(%) 31 (73.8) 16 (76.2) 15 (71.4) 0.73
Age (y) 64.5 (56.8–71.0) 63.0 (55.5–71.0) 65.0 (59.0–70.5) 0.65
BMI(kg/m2) 23.7 (21.9–26.1) 23.8 (21.7–26.3) 23.5 (22.4–26.3) 0.79
HbA1c(%) 9.2 (7.9–10.6) 9.3 (8.1–11.3) 8.9 (7.7–10.0) 0.24
Duration of SU drug use (y) 11.0 (6.0–15.3) 11.0 (5.0–16.5) 10.0 (6.5–15.0) 0.76
Data are expressed as frequencies (%), or median (inter quartile range). The sex ratio between the groups were compared using chi-square test. 
The medians of other data were compared using Wilcoxon rank-sum test. BMI: Body Mass Index. SU: sulfonylurea.Cardiovascular Diabetology 2008, 7:16 http://www.cardiab.com/content/7/1/16
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Median percentage Change from Baseline to 6 months in HbA1c, BMI, Insulin dose/BW, Max IMT, Adiponectin, QOL Figure 2
Median percentage Change from Baseline to 6 months in HbA1c, BMI, Insulin dose/BW, Max IMT, Adiponec-
tin, QOL. The box-and-whisker plots represented medians and inter quartile ranges and ranges. The medians of each data 
were compared using Wilcoxon rank-sum test. BMI; body mass index, BW; body weight, Max IMT; maximum intima media 
thickness, QOL; quality of life.
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injection regimen assigned at randomization and never
had the opportunity to experience the other injection reg-
imen. Therefore, it was felt that a crossover study might be
required to account for differences, if any, in QOL associ-
ated with either injection regimen.
After the DCCT and Kumamoto study that demonstrated
the efficacy of insulin therapy in type 1 and type 2 diabe-
tes, the advent of biphasic insulin formulations has added
to the diversity of insulin regimens available. Thus, there
are a number of studies reported that compared insulin
therapy with a biphasic insulin analogue and that with an
ultra rapid-acting insulin analogue as in the current study.
Of these, Joshi et al. [26] reported that HbA1c improved
better with twice-daily insulin therapy using a biphasic
insulin analogue than with basal-bolus insulin therapy
using an ultra rapid-acting insulin analogue, while a
recently published report from the 4-T study [27] showed
that conventional therapy with a biphasic insulin ana-
logue and basal-bolus therapy with an ultra rapid-acting
insulin analogue produce comparable reductions in
HbA1c. However, these reports provided very little insight
into the impact of insulin therapy on diabetic complica-
tions, particularly progression of atherosclerosis. In this
regard, ours is the first to demonstrate that there is no sig-
nificant difference between the insulin regimens com-
pared in their impact on progression of IMT.
In this study, as there was an increase in glucose levels
after lunch in some patients given the twice-daily regi-
men, Further research will be necessary regarding the
effectiveness of additional daytime insulin injections or
for additional OHA in the individual patient in 30 Mix
group.
Conclusion
This study findings suggest that both basal-bolus therapy
with the ultra rapid-acting insulin analogue and conven-
tional therapy with the twice-daily biphasic insulin ana-
logue produce comparable reductions in HbA1c in type 2
diabetic patients with secondary failure, and that given no
difference seen between both the regimens in glycemic
control, progression of atherosclerosis, and improvement
in QOL. The basal-bolus insulin therapy may not be nec-
essarily needed if the type 2 diabetic patients have become
secondary failure.
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Median percentage Change from Baseline to 6 
months in daily profile of self-measured capillary glu-
cose. The box-and-whisker plots represented medians and 
inter quartile ranges and ranges. No significant difference was 
found between the both group in any time.
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